Astellas Pharma (4503) · InitiativeAchieved
Termination of the Technology License Agreement with Proteostasis Therapeutics for a Therapeutic Agent that Modulates the Endoplasmic Reticulum Stress Response
First written in FY2019-Q3. 1 of 1 entries say "Achieved", first in FY2019-Q3. Latest entry: FY2019-Q3.
1entries
1years
0from disclosures
How it moved
Same theme, other companies
Termination of technology in-licensing agreement with Proteostasis for therapeutics that modulate the endoplasmic reticulum stress responseA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first